The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial
- PMID: 33685036
- PMCID: PMC8016683
- DOI: 10.30773/pi.2020.0329
The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial
Abstract
Objective: This study aimed to investigate treatment effects of combination therapy of memantine and acetylcholinesterase inhibitors (AchEIs) compared with AchEIs alone on behavioral and psychological symptoms of dementia (BPSD) in patients with moderate Alzheimer's dementia (AD).
Methods: This was a 12-week, double-blind, randomized, placebo-controlled trial. A total of 148 patients with moderate AD participated in this study. Mini-Mental State Examination, Neuropsychiatric Inventory (NPI), Clinician's Interview-Based Impression of Change plus caregiver input, Gottfries-Bråne-Steen Scale, and Zarit Burden Interview were used as assessment scales.
Results: There were no significant differences in age, sex, or education between AChEIs alone and combination groups. The combination group showed significantly more improvement of NPI-disinhibition score (0.76±2.15) than the AChEIs alone group (-0.14±1.71) after 12 weeks.
Conclusion: Our findings suggest that the combination therapy of memantine and AchEIs might be a beneficial option for reducing disinhibition symptoms of patients with moderate AD compared with AchEIs alone. We believe that clinicians need to consider additional memantine treatment when patients with moderate AD complain disinhibition symptom. A larger clinical trial is needed to further determine the efficacy and advantages of such combination therapy of memantine and AchEIs for treating BPSD of patients with moderate AD.
Keywords: Acetylcholinesterase inhibitors; Alzheimer’s dementia; Behavioral and psychological symptoms of dementia; Disinhibition; Memantine; Neuropsychiatric inventory.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Figures
References
-
- Xu J, Qiu C. Worldwide Economic Costs and Societal Burden of Dementia. In: Perneczky R, editor. Biomarkers for Preclinical Alzheimer’s Disease. New York: Springer; 2018. pp. 3–13.
-
- National Institute of Dementia . Korean Dementia Observatory 2019. Seoul: Ministry of Health and Welfare, National Institute of Dementia; 2020.
-
- Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–408. - PubMed
-
- Lowery D, Warner J. Behavioural and psychological symptoms of dementia (BPSD): the personal and practical costs of dementia. J Integr Care. 2009;17:13–19.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
